CARLSBAD, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), today announced that, following the Company’s announcement of its strategic realignment of resources and corporate restructuring and release of its third quarter results on November 8, 2023, the Company will no longer hold its third quarter results conference call and webcast which was previously scheduled for Monday, November 13, 2023.
About Acutus Medical, Inc.
Acutus is focused on the production of left-heart access products under its distribution agreement with Medtronic, Inc. Founded in 2011, Acutus is based in Carlsbad, California.
| Investor Contact: |
| Chad Hollister |
| Acutus Medical, Inc. |
| D: 442-232-6080 |
| This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Last Trade: | US$0.04 |
| Daily Change: | -0.05 -53.33 |
| Daily Volume: | 19,666 |
| Market Cap: | US$1.260M |
November 08, 2023 August 07, 2023 May 15, 2023 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
